| Name | Title | Contact Details |
|---|
Babeskin Bodycare is a Scottsdale, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Partners Med B is a Jersey City, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Zanthion protects the elderly from harm, automatically notifies near responders to avoid catastrophic damage, offers solace until help arrives, predicts future needs through artificial intelligence, and connects seniors to the world and their community. Zanthion is a pioneer in changing our social environment with future vision and use case (solution based) systems that improve the world based on open source, transparent, crowdsourced economic mechanisms that accurately assess what happened, inform the correct resources that the event has occurred, provide resources to the problem efficiently, and keep track of the efficiency of fixing the non-conformity. Our platform is generic and it is open. We embrace a responsible future.
Conkerexe Biosciences is a Tempe, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.